// App-Quantinova.ai

1049 : Pharmacological characterization of a novel potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with robust in vivo efficacy and increased therapeutic index with niacin supplementation

Researchers

Presenter

  • Maria Quanz

Principal Investigators

  • Claudia Merz

  • Andreas Bernthaler

  • Stefan Kaulfuss

  • Anja Richter

  • Marcus Bauser

  • Andrea Haegebarth

Medical Centers

  • Bayer Pharma AG, Berlin, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Hematological malignancies

  • Small cell lung cancer

  • Lung Cancer

  • Solid malignancies

  • Campomelic dysplasia

Biomarkers

  • N/A

Drug/Treatment

  • Nicotinamide

  • folitixorin calcium

  • Niacor

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved